Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Osteopore Ltd. ( (AU:OSX) ) is now available.
Osteopore Limited has secured non-exclusive distribution rights from the Biomedical division of dsm-firmenich for an injectable regenerative bone filler in Southeast Asia, adding a complementary product to its orthopaedics portfolio. The minimally invasive filler can treat various bone defects and fill irregular gaps common in trauma and reconstruction surgeries.
The agreement broadens Osteopore’s revenue base by enabling distribution of third-party medical devices, while also signalling increased confidence in its commercialisation capabilities from larger industry players. By targeting the Southeast Asian share of the fast-growing Asia-Pacific orthobiologics and bone graft substitutes market, estimated at roughly AUD 94.6 million to AUD 284 million and underpinned by rising procedure volumes and healthcare spending, Osteopore strengthens its regional growth prospects.
The most recent analyst rating on (AU:OSX) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
More about Osteopore Ltd.
Osteopore Limited is an Australian-Singaporean regenerative medicine company that develops 3D-printed biomimetic and bioresorbable implants for use in orthopaedics and related surgical applications. The company focuses on minimally invasive solutions for bone regeneration and reconstruction, targeting fast-growing orthobiologics and bone graft substitute markets in the Asia-Pacific region.
Average Trading Volume: 31,878,288
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.94M
For an in-depth examination of OSX stock, go to TipRanks’ Overview page.